Tag: SAR3419
ADC Market to Reach US$ 3 Billion by 2018
According to a report published by Research & Markets, one of the world's largest and most respected market research resource, the global market for Antibody-drug...
SAR3419 Achieved Objective Responses Well Above Study Threshold and was Found...
A novel anticancer therapeutic called coltuximab ravtansine (CoR; SAR3419; Sanofi) shows favorable results in the Phase II STARLYTE trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a humanized CD19 mAb linked to DM4, a maytansine analog, developed by ImmunoGen.
